



EPILEPSY
FOUNDATION®

pipeline
conference



HYBRID IN-PERSON & VIRTUAL EVENT
SUNDAY, JUNE 5 – MONDAY, JUNE 6, 2022
SANTA CLARA MARRIOTT
SANTA CLARA, CALIFORNIA

TABLE OF CONTENTS

About Pipeline Conference	p 3
Conference Agenda	p 4
2022 Epilepsy Foundation Lifetime Accelerator Award Recipient.....	p 12
Sponsor Acknowledgements	p 13
Logistical Information & Zoom Details	p 14
Pipeline Conference Mobile App Guide	p 16
About Us	p 17
Notes.....	p 18

About Pipeline Conference

The Epilepsy Foundation's Pipeline Conference showcases the latest developments in the epilepsy pipeline from pre-clinical to right before approval. The event features industry leaders from around the world who come together every two years to share ideas and provide insights in the field of epilepsy treatment, therapeutic innovation, and product development. The conference provides a forum for surveying new therapies in development, exploring future advancements, and encouraging collaborations and partnerships.

About our Research Efforts

Epilepsy is broadly underfunded and especially so in the translation of research insights into new therapies. The Epilepsy Foundation has dedicated a significant part of its mission to ensuring the best and the brightest young investigators get a chance to become involved in epilepsy and seizure research. In addition, the Foundation's investment in new therapies and research is 100% focused on bringing better treatments in a timeframe that matters to people living with epilepsy and seizures. It is part of the Foundation's unwavering commitment to the epilepsy community.

AGENDA OVERVIEW

SUNDAY, JUNE 5, 2022

7:00am-8:30am **Breakfast and Registration**

8:30am-8:45am **Welcome and Introduction**
Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation
R. Edward Hogan, MD, President, American Epilepsy Society
Helen Cross, MD, President, International League Against Epilepsy

SESSION I: IMPACT OF COVID ON CLINICAL TRIALS

Moderator: Kimford Meador, MD

8:45am-8:50am **Patient/Caregiver Perspective**
Kim Nye, TESS Research Foundation

8:50am-9:10am **Panel Discussion: Is COVID Helping or Hurting Drug Development?**
Moderator: Jacqueline French, MD, Epilepsy Foundation
R. Edward Hogan, MD, American Epilepsy Society
Elaine Wirrell, MD, Mayo Clinic
Kathryn Davis, MD, University of Pennsylvania
Lilly Frohlich, MPH, Cerevel Therapeutics
Kim Nye, TESS Research Foundation

9:10am-9:25am **Remote Trial Design**
Penny Randall, MD, MBA, IQVIA

9:25am-9:40am **Q&A**

SESSION II: PRECLINICAL PIPELINE

Moderator: Pavel Klein MD, FAAN, FAES

9:40am-9:50am **BL-001 (drug candidate) / IrisRx Platform**
Chris Reyes, PhD, Bloom Science

9:50am-10:00am **Preclinical Data Supporting the Efficacy of OV329, A Next-Generation GABA Aminotransferase Inhibitor, Against Seizures**
Julia Tsai, PhD, Ovid

10:00am-10:15am **Networking Break**

AGENDA OVERVIEW

SESSION III: PERSONALIZED MEDICINE: HOW FAR HAVE WE COME AND WHERE ARE WE GOING?

Moderator: Brandy Fureman, PhD

10:15am-10:20am	Patient/Caregiver Perspective <i>Daniel Fischer, SCN1A</i>
10:20am-10:35am	Specific Gene Mutation Screening in Infants: Who are We Finding and Who are We Missing? <i>Mark Fitzgerald, MD, PhD, Children's Hospital of Philadelphia</i>
10:35am-10:50am	Gene Based Therapies: Why are They Likely to Succeed, Why are They Likely to Fail? <i>Annapurna Poduri, MD, MPH, Boston Children's Hospital</i>
10:50am-11:10am	Panel Discussion <i>Moderator: Brandy Fureman, PhD, Epilepsy Foundation</i> <i>Daniel Fischer, SCN1A</i> <i>Mark Fitzgerald, MD, PhD, Children's Hospital of Philadelphia</i> <i>Annapurna Poduri, MD, MPH, Boston Children's Hospital</i>

SESSION IV: PIPELINE FOR GENE BASED THERAPIES

Moderator: Dennis Dlugos, MD, MSCE

11:10am-11:20am	Behind the Seizures Program <i>Nasha Fitter, Invitae</i>
11:20am-11:30am	NRTX-1001: Inhibitory Neuron Cell Therapy for Drug-Resistant Temporal Lobe Epilepsy <i>Cory Nicholas, PhD, Neurona Therapeutics</i>
11:30am-11:40am	Developing STK-001: An Antisense Oligonucleotide Treatment for Dravet Syndrome <i>Kimberly Parkerson, MD, PhD, Stoke Therapeutics</i>
11:40am-11:50am	NEUmiRNA Therapeutics: Aspiring to Cure Epilepsy <i>Henrik Klitgaard, PhD, NEUmiRNA Therapeutics</i>
11:50am-12:00pm	CODA Chemogenetic Receptor/Activator Drug <i>Susan Catalano, PhD, CODA Biotherapeutics, Inc.</i>
12:00pm-12:10pm	Newly Anticipated ASO Therapeutic for a Genetic Target <i>Viet Nguyen, MD, Biogen</i>
12:10pm-12:20pm	CAMP-4 <i>Alfica Sehgal, PhD</i>

AGENDA OVERVIEW

SESSION V: DIGITAL/DEVICE

Moderator: Robert Fisher, MD, PhD

1:20pm-1:30pm	EmbracePlus <i>Matteo Lai, Empatica</i>
1:30pm-1:40pm	Epiminder <i>Mark Cook, MD, Epiminder</i>
1:40pm-1:50pm	Seer - Long-Term At-Home Epilepsy Monitoring <i>Dean Freestone, PhD, Seer Medical</i>
1:50pm-2:00pm	Epihunter Absence: Clinical Validation <i>Dirk Loeckx, PhD, MBA, Epihunter</i>
2:00pm-2:10pm	REMI: Remote EEG Monitoring <i>Kris Kahlig, PhD, Praxis Precision Medicines</i>
2:10pm-2:20pm	UNEEG 24/7 EEG™ SubQ <i>Lykke Blaabjerg, MSc, PhD, UNEEG Medical A/S</i>
2:20pm-2:30pm	Replacing Trying with Knowing in Epilepsy Care <i>John Hixson, MD, Nile</i>
2:30pm-2:40pm	EpiCare@Home: Enabling Virtual Epilepsy Care <i>Julie Nys, PhD, Byteflies</i>
2:40pm-3:10pm	Networking Break

SHARK TANK

Moderator: Tom Stanton, Danny Did Foundation

3:10pm-3:15pm	Shark Tank Welcome <i>Laura Thrall, President & CEO, Epilepsy Foundation</i>
3:15pm-3:20pm	2021 Community Prize Winner Update: An Epilepsy Self-Management and Resilience Technical App (SMART) for Adolescents & their Community <i>Deborah Koltai, PhD, Duke University</i>
3:20pm-3:25pm	2021 Investment Award Winner Update: Generalized Tonic-Clonic Seizure Detection with Video and Radar <i>Tobias Loddenkemper, MD, Miku</i>
3:25pm-3:30pm	Introductions and Rules <i>Tom Stanton, Danny Did Foundation</i>

AGENDA OVERVIEW

Sharks:

Kathryn Davis, MD, University of Pennsylvania

Brandy Fureman, PhD, Epilepsy Foundation

R. Edward Hogan, MD, American Epilepsy Society

David B. Moore, MD, McFarland Clinic

Noah Richmond, JD, PhD, Verily Life Sciences

Community Impact Award

An Openscience Community Developing a Smart Connected Patch to Detect Epilepsy Seizures

Clement Le Couedic, AURA Ngo

EpiPal: A Patient- and Family-Centered Software Platform for Seizure Detection, Epilepsy Safety and Management, and Treatment Insights

Amir Helmy, Epipal

Predictive Seizure Alert App

Serge Lauriou, My Medic Watch

Investment Award

Novel Electrodes for Brain Mapping and Assessment of Epilepsy Surgery Candidates

Pierre Wijdenes, PhD, Neuraura Biotech, Inc

Biomarker of Early Detection of Epilepsy After Head Injury to Facilitate Proof of Principle Study of Treatment to Prevent Post-Traumatic Epilepsy

Pavel Klein, MD, FAES, FAAN, PrevEP, Inc.

Predictive Analytics for Brain Surgery

Max Sims, MBA / Brad Mahon, MindTrace Technologies, Inc.

Award Presentation

Jacqueline French, MD, Epilepsy Foundation

5:00pm-5:30pm

2022 May Liang & James Lintott Scholarship Recipients

Wesley Kerr, MD, PhD, University of Michigan

Katie Ihnen, MD, PhD, Cincinnati Children's Hospital

2022 Epilepsy Foundation Lifetime Accelerator Award

Lynn Kramer, MD, FAAN

6:00pm

Dinner Reception

AGENDA OVERVIEW

MONDAY, JUNE 6, 2022	
7:00am-8:00am	Continental Breakfast and Registration
8:00am-8:05am	Welcome and Remarks from This Year's Innovator Sponsor, SK Life Science <i>Laura Thrall, President & CEO, Epilepsy Foundation</i>
8:05am-8:15am	The Digital Imperative: Serving the Epilepsy Community <i>Laura Thrall, President & CEO, Epilepsy Foundation</i>
SESSION VI: NEW TECHNOLOGY ADOPTION <i>Moderator: R. Edward Hogan, MD</i>	
8:15am-8:20am	Patient/Caregiver Perspective <i>Noah Richmond, JD, PhD, Verily Life Sciences</i>
8:20am-8:35am	Machine Learning in Health: An Introduction into Machine Learning and Applications in Healthcare including Conditions Analysis Work in Care Studio <i>Paul Muret, Google</i>
8:35am-8:50am	Seizure Detection Devices: Parental Needs, Coping, and How Devices Fit <i>Anouk van Westrhenen, MD, SEIN & LUMC, the Netherlands</i>
8:50am-9:20am	Discussion: Obtaining Seizure Data Using Remote Monitoring/ Devices
9:20am-9:35am	Focus on Reimbursement and Market Access <i>Jo Ellen Slurzberg, JR Associates, Inc.</i>
9:35am-9:50am	Making the Case for your Value Proposition to Payers <i>Ian Duncan, PhD, Santa Barbara Actuaries Inc.</i>
9:50am-10:20am	Panel Discussion: Reimbursement <i>Moderator: R. Edward Hogan, MD</i> <i>Jo Ellen Slurzberg, JR Associates, Inc.</i> <i>Ian Duncan, PhD, Santa Barbara Actuaries Inc.</i>
10:20am-10:40am	Networking Break

AGENDA OVERVIEW

SESSION VII: DEVICES

Moderator: Hina Dave, MD

10:40am-10:50am **Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology: SeizeIT2**
Lauren Swinnen, KU Leuven

10:50am-11:00am **A New Paradigm in Neurocare Enabled by Unobtrusive Brain Monitoring**
Jennifer Dwyer, MD, PhD, NextSense

11:00am-11:10am **NeuroHelp: Epiness**
Oren Shriki, PhD, NeuroHelp

11:10am-11:20am **Reinventing Brain Health: Personalized Technologies for Brain Monitoring and Stimulation**
Giulio Ruffini, PhD, Neuroelectrics

11:20am-11:30am **Focused Ultrasound Foundation is an Image-Guided, Noninvasive, Non-Ionizing Therapeutic Technology**
Vibhor Krishna, MD, SM, Focused Ultrasound

11:30am-12:40pm **Networking Lunch**

SESSION VIII: CREATING EQUITABLE AND INFORMATIVE TRIALS

Moderator: Caitlin Grzeskowiak, PhD

12:40pm-12:45pm **Patient/Caregiver Perspective**
Representative Iman Jodeh, Colorado House of Representatives

12:45pm-1:00pm **Focusing Drug Trials: Seizure, Etiology or Syndrome?**
Elaine Wirrell, MD, Mayo Clinic

1:00pm-1:15pm **Advancing Clinical Trial Diversity at Pfizer**
Rene Lopez, MPH, Pfizer

1:15pm-1:30pm **Achieving Patient Focused Drug Development - Why are Measures that are Used, Used?**
James Mitchell, MBChB, University of Liverpool

1:30pm-1:45pm **Basket Trials**
Kert Viele, PhD, Berry Consultants

1:45pm-2:15pm **Q&A**

2:15pm-2:30pm **Networking Break**

AGENDA OVERVIEW

SESSION IX: CLINICAL DRUGS

Moderator: Jacqueline French, MD

2:30pm-2:40pm	Rozanolixizumab in Leucine-Rich Glioma-Inactivated 1 Autoimmune Encephalitis: The LEGIONE Study <i>Stephen Yates, PhD, UCB Pharma</i>
2:40pm-2:50pm	Neurocrine Biosciences NBI-921352-DEE2012 Clinical Program Overview <i>Brian Moseley, MD, Neurocrine Biosciences, Inc.</i>
2:50pm-3:00pm	Abi-009 Surgically Refractory Epilepsy <i>Jason Hauptman, Seattle Children's Hospital</i>
3:00pm-3:10pm	ENX-101 <i>Eve Taylor, Engrail</i>
3:10pm-3:20pm	PRAX-562 and Praxis Pipeline Updates <i>Kris Kahlig, PhD, Praxis Precision Medicines</i>
3:20pm-3:30pm	Ganaxolone <i>Joseph Hulihan, MD, Marinus Pharmaceuticals, Inc.</i>
3:30pm-3:40pm	XEN1101 - Next Generation KV7 Channel Opener <i>Chris Kenney, MD, FAAN, Xenon Pharmaceuticals</i>
3:40pm-3:50pm	Intraventricular Therapy for Epilepsy <i>Eric Distad, Cerebral Therapeutics, Inc.</i>
3:50pm-4:00pm	LP352: A Selective 5HT2c Agonist for Developmental and Epileptic Encephalopathies <i>Randall Kaye, MD, Longboard Pharmaceuticals</i>
4:00pm-4:10pm	Darigabat: REALIZE Trial Progress <i>Lilly Frohlich, MPH, Cerevel Therapeutics</i>
4:10pm-4:20pm	LPCN 2101, an Endogenous Neuroactive Steroid for Epilepsy <i>Ben Bruno, PharmD, PhD, Lipocine</i>
4:20pm-4:30pm	Staccato® alprazolam <i>Robert Roebing, MD, UCB</i>

AGENDA OVERVIEW

4:30pm-4:40pm	Radiprodil: A NR2B-NMDA Negative Allosteric Modulator, for GRIN-Related Disorder caused by Gain of Function Mutations <i>Pierandrea Muglia, MD, GRIN Therapeutics</i>
4:40pm-4:50pm	ETX-155, A Novel GABAA Positive Allosteric Modulator <i>Mark Versavel, MD, PhD, MBA, Eliem Therapeutics, Inc.</i>
4:50pm-5:00pm	Novel Hypothesis-Generating Analysis of Intervals between Seizure Clusters <i>Sunita Misra, MD, PhD, Neurelis Inc.</i>
5:00pm-5:10pm	CLOSING REMARKS <i>Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation</i>



2022 EPILEPSY FOUNDATION LIFETIME ACCELERATOR AWARD RECIPIENT

**LYNN D. KRAMER MD, FAAN
CHIEF CLINICAL OFFICER,
NEUROLOGY BUSINESS GROUP**

Lynn D. Kramer, MD, FAAN, is Chief Clinical Officer, Neurology Business Group at Eisai and a member of the Eisai Company Ltd. Executive Committee. In these roles, he oversees the product creation cycle including clinical introduction, and regulatory approval of innovative projects in the neuroscience and general medicine area globally.

Dr. Kramer, who has been with Eisai since 2007, started as the Executive Vice President of Global Clinical Research, and was soon promoted to the additional role of Chief Operating Officer of Eisai Medical Research. In early 2009, he was named President of the Scientific and Operational Clinical Support Core Function Unit (SOCS CFU) and President of the Neuroscience, Product Creation Unit.

He was named Chief Clinical Officer and a member of the Executive Committee, Eisai Company, Ltd. in 2012. In addition to those roles Dr. Kramer was named Chief Medical Officer of the Neuroscience Business Group in April 2016.

Prior to joining Eisai, Dr. Kramer oversaw clinical development, pharmacovigilance, drug safety and medical affairs for PAR Pharmaceutical, Inc. Earlier in his career he held senior positions in drug development such overseeing clinical development and clinical operations at Purdue Pharmaceuticals, was Vice President Clinical Research and Head of the Therapeutic Area Strategy Team at Novartis, and Vice

President Clinical Research at the R.W. Johnson Pharmaceutical Research Institute.

Dr. Kramer is a Fellow of the American Board of Psychiatry and Neurology (1987) and the Philadelphia College of Physicians (1987). He previously served as the industry representative on the Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) and on the Board of Directors at American Society for Experimental Neuro Therapeutics (ASENT). He currently is a member of the Pharma R & D Leadership Forum. He has served on the Executive Committee Board of Trustees of Lycoming College where he received a Bachelor of Arts degree.

Dr. Kramer received his MD from Hahnemann Medical College. He completed his internship in internal medicine at the University of California at Irvine, and his residency in neurology at the University of Virginia. He has been Co-PI on several NIH grants: Clinical and Epidemiologic Studies of Human Epilepsies, Pharmacologic Prophylaxis of Post-Traumatic Epilepsy, and had a Master Agreement Evaluation of Investigational Antiepileptic Drugs prior to his move into industry. He also holds a Bachelor of Arts degree from Lycoming College, where he since had served on the Executive Committee Board of Trustees.

SPONSORS ACKNOWLEDGEMENT

Thank you for your support to make the 2022 Epilepsy Foundation Pipeline Conference a successful event and your commitment to the epilepsy community.

INNOVATOR SPONSOR



EXPLORER SPONSORS



NEURELIS



Inspired by patients.
Driven by science.

ZOGENIX

Now a part of UCB

PIONEER SPONSORS



JUNE 5-6, 2022
SANTA CLARA, CA


2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE LOGISTICAL INFORMATION & ZOOM DETAILS

Zoom Session FYIs

- Connect to a stable internet connection. A wired connection is best, but not required.
- It is recommended to use computer audio on Zoom during the conference, but it is not required.
- The Zoom link for the conference can be found below.
- Please remember to MUTE and reduce noise where possible.

Zoom Details for the Epilepsy Foundation Pipeline Conference

- We will begin promptly at 8:30am PT on Sunday, June 5 and 8:00am PT on Monday, June 6.
- Please allow yourself time to log on and update your participant name. You may want to consider logging on 5-10 minutes ahead of time.
- Upon joining, you will automatically be muted. Please remain muted until instructed otherwise.



Zoom Link

Pipeline Conference Day 1: <https://us06web.zoom.us/j/89908092521?pwd=RFZXcm1xbDFJNFozQURnVHErSXFzdz09>

Meeting ID: 899 0809 2521

Passcode: 601626

Pipeline Conference Day 2: <https://us06web.zoom.us/j/89566226196?pwd=TUJpUVNyaEtKZWl2SWdiQjZOUVI4UT09>

Meeting ID: 895 6622 6196

Passcode: 02985

Participate in the Conference

- To ask or answer a question, or otherwise share aloud, use the “Raise Hand” function in Zoom. This function can be found in the Participant List.
- All attendees are welcome to participate in the chat box.

LOGISTICAL INFORMATION & ZOOM DETAILS (CONT)

1. Join Zoom via the Zoom application.


- Free application can be downloaded here: <https://zoom.us/support/download>.
- May need administrative approval to download application.

2. Test your computer's connection and audio settings prior to joining the meeting.

- You can do so here: <https://zoom.us/test>.
- May need administrative approval to download application.

3. Join audio by choosing one of the options when prompted. Computer audio is highly recommended.

- If you must join via phone, enter “#” + Participation ID + “#” on your phone.
- Hit MUTE to minimize background noise when you are not speaking.
- NOTE: If you are joining by phone, you may need to unmute on your Zoom dashboard and your phone.



4. Change your name.

- Find your name in the Participants List. Hint: It will say “Me” at the end.
- Hover over your name to see a blue button that says “Rename” and click “Rename.”
- Change your name to: [FIRST NAME] [LAST NAME]. Example: John Smith.

If you are experiencing problems, contact Zoom for personal help. They are available 24 hours a day, seven days a week at 1-888-799-9666 extension 2.

ABOUT THE EPILEPSY FOUNDATION



Our mission is to lead the fight to overcome the challenges of living with the epilepsies and to accelerate therapies to stop seizures, find cures, and save lives.

Only a small fraction of the 3.4 million Americans affected by the epilepsies are directly engaged with the Foundation network. People with epilepsy continue to experience stigma around the condition, and diminished opportunities for education and employment. Health disparities and unequal access to care plague our systems. Federal funds appropriated for epilepsy research lag in comparison to other diseases with far lower prevalence. After decades of new therapy development, we are still controlling the symptoms - the seizures - without modifying the course of the disease or preventing it from happening in those at risk.

Working with our community and network partners, the EPILEPSY FOUNDATION connects the people, data and resources needed to address challenging health problems associated with seizures and the epilepsies—and promotes education, policy, research and systemic change that will foster measurable and sustainable improvement for all people living with epilepsy.

Our strategic vision for 2020 - 2025 has five objectives (the 'Five Pillars'). These Pillars were identified through surveys and collaborative discussions with our stakeholders during 2018 - 2019 and were endorsed by our Board of Directors. They create a bedrock for the structure of our organizational priorities over the next five years.



The mission of the Epilepsy Foundation
is to lead the fight to overcome
the challenges of living with epilepsy
and to accelerate therapies
to stop seizures, find cures, and save lives.

Learn more at epilepsy.com